FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

l	OMB APPRO	OVAL					
	OMB Number:	3235-0287					
l	Estimated average burd	en					
l	hours per response:	0.5					

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Aberman Michael S</u>							2. Issuer Name and Ticker or Trading Symbol REGENERON PHARMACEUTICALS INC [REGN]											5. Relationship of Reporting Person(s) to Issu (Check all applicable) Director 10% Own X Officer (give title Other (sp				
(Last) 777 OLD	,	(First) (Middle) SAW MILL RIVER ROAD						3. Date of Earliest Transaction (Month/Day/Year) 08/22/2014											nd Inv	below) vestor Rela	nt	
(Street) TARRYTOWN NY 10591						4. If Amendment, Date of Original Filed (Month/Day/Year)										Individual or Joint/Group Filing (Check Applicable ne) X Form filed by One Reporting Person Form filed by More than One Reporting					n	
(City) (State) (Zip)																	Person					
		Tab	le I - Nor	ո-Deriv	ative	Se	curiti	ies Ad	cqui	ired, [Disp	osed c	of, or	Ben	eficia	lly	Owned	ł				
1. Title of Security (Instr. 3) 2. Trans Date (Month/						ar)	2A. Deemed Execution Date, if any (Month/Day/Year)		е,	3. Transaction Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 5)				4 and Securiti Benefic Owned		es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership	
								Code	v	Amount	ount (A) or (D)		Price		Reported Transact (Instr. 3	tion(s)			Instr. 4)			
Common	Stock	2/201	4				M		3,00	0	Α	\$24	!4 18		,600		D					
Common Stock																	3	76		I	By 401(k) Plan	
		7	able II -	Deriva (e.g., p												<i>y</i> 0	wned			,		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	Date,	4. Transa Code (8)		of		Exp	Pate Exe piration I onth/Day	Date		7. Title and Amount of Securities Underlying Derivative Secur (Instr. 3 and 4)			De	Price of erivative ecurity estr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly C	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exe	e ercisable		xpiration ate	Title	0 0	Amount or Jumber of Shares							
Incentive Stock Option (right to	\$24	08/22/2014			M			3,000		(1)	03	/22/2020	Comm		3,000		\$0.0	8,064		D		

Explanation of Responses:

1. The stock option award (combined incentive stock option and non-qualified stock option) vests over five years, commencing one year after the date of grant. 12,500 options vest on the first anniversary, 25,000 options vest on the second anniversary, 25,000 options vest on the first anniversary and 12,500 options vest on the fifth anniversary of the date of grant.

/s/**Michael S. Aberman

08/26/2014

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.